World News: 12:00 GMT Monday 20th March 2017. [Checkpoint Therapeutics, Inc via Globe Newswire via SPi World News]
NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that preclinical data on its anti-PD-L1 antibody and EGFR inhibitor programs will be presented in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2017, to be held April 1-5, at the Walter E. Washington Convention Center in Washington, D.C.
Details on the poster presentations are as follows:
For additional information, please visit the AACR website: .
Checkpoint Therapeutics, Inc.
Fortress Biotech Media Relations
(312) 448-8098; email@example.com
Globe Newswire: 12:00 GMT Monday 20th March 2017
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.